Mark A. Murcko

16.0k total citations · 8 hit papers
72 papers, 10.8k citations indexed

About

Mark A. Murcko is a scholar working on Molecular Biology, Organic Chemistry and Computational Theory and Mathematics. According to data from OpenAlex, Mark A. Murcko has authored 72 papers receiving a total of 10.8k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Molecular Biology, 21 papers in Organic Chemistry and 19 papers in Computational Theory and Mathematics. Recurrent topics in Mark A. Murcko's work include Computational Drug Discovery Methods (19 papers), Advanced Chemical Physics Studies (9 papers) and Chemical Synthesis and Analysis (8 papers). Mark A. Murcko is often cited by papers focused on Computational Drug Discovery Methods (19 papers), Advanced Chemical Physics Studies (9 papers) and Chemical Synthesis and Analysis (8 papers). Mark A. Murcko collaborates with scholars based in United States, France and United Kingdom. Mark A. Murcko's co-authors include Guy W. Bemis, W. Patrick Walters, Kenneth B. Wiberg, Matthew T. Stahl, Ajay, Paul R. Caron, Keith P. Wilson, Manuel A. Navia, Stephen P. Chambers and Paul S. Charifson and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Mark A. Murcko

72 papers receiving 10.2k citations

Hit Papers

The Properties of Known Drugs. 1. Molecular Frameworks 1994 2026 2004 2015 1996 1994 1998 1996 1998 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The Properties of Known Drugs. 1. Molecular Frameworks
    1996 1.7k citations Guy W. Bemis, Mark A. Murcko Journal of Medicinal Chemistry profile →
  2. Structure and mechanism of interleukin-lβ converting enzyme
    1994 705 citations Keith P. Wilson, John A. Thomson et al. Nature profile →
  3. Virtual screening—an overview
    1998 698 citations W. Patrick Walters, Mark A. Murcko et al. profile →
  4. Crystal Structure of the Hepatitis C Virus NS3 Protease Domain Complexed with a Synthetic NS4A Cofactor Peptide
    1996 554 citations Kurt Morgenstern, Chao Lin et al. Cell profile →
  5. Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding
    1998 518 citations Joseph L. Kim, Kurt Morgenstern et al. Structure profile →
  6. Consensus Scoring:  A Method for Obtaining Improved Hit Rates from Docking Databases of Three-Dimensional Structures into Proteins
    1999 517 citations Paul S. Charifson, Mark A. Murcko et al. Journal of Medicinal Chemistry profile →
  7. What Do Medicinal Chemists Actually Make? A 50-Year Retrospective
    2011 303 citations W. Patrick Walters, Mark A. Murcko et al. Journal of Medicinal Chemistry profile →
  8. Modulating biomolecular condensates: a novel approach to drug discovery
    2022 218 citations Diana M. Mitrea, Matthäus Mittasch et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark A. Murcko United States 43 6.1k 4.0k 2.3k 1.2k 1.1k 72 10.8k
Andrew L. Hopkins United Kingdom 30 9.1k 1.5× 5.0k 1.2× 1.9k 0.8× 803 0.7× 680 0.6× 63 14.2k
Bernd Kuhn Switzerland 43 6.9k 1.1× 2.6k 0.6× 3.5k 1.5× 1.4k 1.2× 889 0.8× 109 12.7k
Kaixian Chen China 58 7.5k 1.2× 3.5k 0.9× 2.9k 1.3× 1.7k 1.4× 804 0.7× 437 13.9k
Jason K. Perry United States 28 5.5k 0.9× 3.1k 0.8× 1.9k 0.8× 809 0.7× 263 0.2× 60 10.3k
Jay L. Banks United States 6 8.3k 1.4× 4.7k 1.2× 3.0k 1.3× 1.1k 0.9× 404 0.4× 8 13.4k
Daniel T. Mainz United States 9 9.0k 1.5× 4.8k 1.2× 3.4k 1.4× 1.1k 1.0× 414 0.4× 11 14.7k
Peter S. Shenkin United States 19 7.4k 1.2× 3.4k 0.8× 2.1k 0.9× 1.4k 1.2× 512 0.5× 28 11.1k
F. Javier Luque Spain 70 8.0k 1.3× 2.7k 0.7× 5.4k 2.3× 1.7k 1.4× 2.0k 1.8× 393 16.9k
Tyler Day United States 22 6.1k 1.0× 2.7k 0.7× 1.9k 0.8× 760 0.7× 491 0.5× 24 10.4k
Matthew P. Repasky United States 18 9.5k 1.6× 5.3k 1.3× 3.7k 1.6× 1.3k 1.1× 437 0.4× 20 15.6k

Countries citing papers authored by Mark A. Murcko

Since Specialization
Citations

This map shows the geographic impact of Mark A. Murcko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Murcko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Murcko more than expected).

Fields of papers citing papers by Mark A. Murcko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Murcko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Murcko. The network helps show where Mark A. Murcko may publish in the future.

Co-authorship network of co-authors of Mark A. Murcko

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Murcko. A scholar is included among the top collaborators of Mark A. Murcko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Murcko. Mark A. Murcko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fraser, James S. & Mark A. Murcko. (2024). Structure is beauty, but not always truth. Cell. 187(3). 517–520. 17 indexed citations
2.
Patel, Avinash, Diana M. Mitrea, Vigneshwaran Namasivayam, et al.. (2022). Principles and functions of condensate modifying drugs. Frontiers in Molecular Biosciences. 9. 1007744–1007744. 31 indexed citations
3.
Mitrea, Diana M., Matthäus Mittasch, Beatriz Ferreira Gomes, Isaac A. Klein, & Mark A. Murcko. (2022). Modulating biomolecular condensates: a novel approach to drug discovery. Nature Reviews Drug Discovery. 21(11). 841–862. 218 indexed citations breakdown →
4.
Murcko, Mark A., et al.. (2020). Assessing the impact of generative AI on medicinal chemistry. Nature Biotechnology. 38(2). 143–145. 133 indexed citations
5.
Byrn, Randal A., Steven J.M. Jones, Michael P. Clark, et al.. (2014). Preclinical Activity of VX-787, a First-in-Class, Orally Bioavailable Inhibitor of the Influenza Virus Polymerase PB2 Subunit. Antimicrobial Agents and Chemotherapy. 59(3). 1569–1582. 149 indexed citations
6.
Murcko, Mark A. & W. Patrick Walters. (2012). Alpha shock. Journal of Computer-Aided Molecular Design. 26(1). 97–102. 4 indexed citations
7.
Perni, Robert B., Gurudatt Chandorkar, Kevin M. Cottrell, et al.. (2007). Inhibitors of hepatitis C virus NS3·4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics. Bioorganic & Medicinal Chemistry Letters. 17(12). 3406–3411. 16 indexed citations
8.
Walters, W. Patrick & Mark A. Murcko. (2002). Prediction of ‘drug-likeness’. Advanced Drug Delivery Reviews. 54(3). 255–271. 342 indexed citations
9.
Fejzo, Jasna, Christopher A. Lepre, Jeffrey W. Peng, et al.. (1999). The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. Chemistry & Biology. 6(10). 755–769. 194 indexed citations
10.
Kim, Joseph L., et al.. (1998). Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure. 6(1). 89–100. 518 indexed citations breakdown →
11.
Wilson, Keith P., Patricia G. McCaffrey, Kathy Hsiao, et al.. (1997). The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chemistry & Biology. 4(6). 423–431. 239 indexed citations
12.
Sintchak, Michael D., Mark Fleming, Olga Futer, et al.. (1996). Structure and Mechanism of Inosine Monophosphate Dehydrogenase in Complex with the Immunosuppressant Mycophenolic Acid. Cell. 85(6). 921–930. 347 indexed citations
13.
DeCenzo, Maureen T., et al.. (1996). FK506-binding protein mutational analysis: defining the active-site residue contributions to catalysis and the stability of ligand complexes. Protein Engineering Design and Selection. 9(2). 173–180. 70 indexed citations
14.
Morgenstern, Kurt, Chao Lin, Ted Fox, et al.. (1996). Crystal Structure of the Hepatitis C Virus NS3 Protease Domain Complexed with a Synthetic NS4A Cofactor Peptide. Cell. 87(2). 343–355. 554 indexed citations breakdown →
15.
Rao, B. Govinda & Mark A. Murcko. (1996). Free energy perturbation studies on binding of A-74704 and its diester analog to HIV-1 protease. Protein Engineering Design and Selection. 9(9). 767–771. 13 indexed citations
16.
Wilson, Keith P., John A. Thomson, Eunice E. Kim, et al.. (1994). Structure and mechanism of interleukin-lβ converting enzyme. Nature. 370(6487). 270–275. 705 indexed citations breakdown →
17.
Murcko, Mark A., et al.. (1993). GenStar: A method for de novo drug design. Journal of Computer-Aided Molecular Design. 7(1). 23–43. 84 indexed citations
18.
Nelson, Patricia A., et al.. (1991). cDNA encoding murine FK506-binding protein (FKBP): nucleotide and deduced amino acid sequences. Gene. 109(2). 255–258. 25 indexed citations
19.
Prugh, John D., George D. Hartman, Pierre Mallorga, et al.. (1991). New isomeric classes of topically active ocular hypotensive carbonic anhydrase inhibitors: 5-substituted thieno[2,3-b]thiophene-2-sulfonamides and 5-substituted thieno[3,2-b]thiophene-2-sulfonamides. Journal of Medicinal Chemistry. 34(6). 1805–1818. 97 indexed citations
20.
Baldwin, John J., G. S. PONTICELLO, Paul Anderson, et al.. (1989). Thienothiopyran-2-sulfonamides: novel topically active carbonic anhydrase inhibitors for the treatment of glaucoma. Journal of Medicinal Chemistry. 32(12). 2510–2513. 157 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrew L. Hopkins Breakdown of academic impact, for papers by Bernd Kuhn Breakdown of academic impact, for papers by Kaixian Chen Breakdown of academic impact, for papers by Jason K. Perry Breakdown of academic impact, for papers by Jay L. Banks Breakdown of academic impact, for papers by Daniel T. Mainz Breakdown of academic impact, for papers by Peter S. Shenkin Breakdown of academic impact, for papers by F. Javier Luque Breakdown of academic impact, for papers by Tyler Day Breakdown of academic impact, for papers by Matthew P. Repasky
Rankless by CCL
2026